Praluent Approval History
FDA Approved: Yes (First approved July 24, 2015)
Brand name: Praluent
Generic name: alirocumab
Dosage form: Injection
Company: Sanofi and Regeneron Pharmaceuticals, Inc.
Treatment for: High Cholesterol, High Cholesterol, Familial Heterozygous
Praluent (alirocumab) is a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor monoclonal antibody for the treatment of patients with heterozygous familial hypercholesterolemia or atherosclerotic heart disease who require additional lowering of LDL-cholesterol.
Development History and FDA Approval Process for Praluent
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.